234 related articles for article (PubMed ID: 30693486)
1. Autoantibodies in acquired myasthenia gravis: Clinical phenotype and immunological correlation.
Nagappa M; Mahadevan A; Gangadhar Y; Patil SA; Bokolia S; Bindu PS; Sinha S; Taly AB
Acta Neurol Scand; 2019 May; 139(5):428-437. PubMed ID: 30693486
[TBL] [Abstract][Full Text] [Related]
2. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients.
Hong Y; Li HF; Skeie GO; Romi F; Hao HJ; Zhang X; Gao X; Owe JF; Gilhus NE
J Neuroimmunol; 2016 Sep; 298():51-7. PubMed ID: 27609275
[TBL] [Abstract][Full Text] [Related]
4. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
Romi F; Skeie GO; Aarli JA; Gilhus NE
Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis.
Wang R; Li J; Wang M; Hao H; Chen X; Li R; Zhu X
Br J Dermatol; 2015 Apr; 172(4):968-75. PubMed ID: 25388377
[TBL] [Abstract][Full Text] [Related]
6. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
Cordts I; Bodart N; Hartmann K; Karagiorgou K; Tzartos JS; Mei L; Reimann J; Van Damme P; Rivner MH; Vigneron A; Weis J; Schulz JB; Tzartos SJ; Claeys KG
J Neurol; 2017 Jun; 264(6):1193-1203. PubMed ID: 28516329
[TBL] [Abstract][Full Text] [Related]
7. Muscle autoantibodies in subgroups of myasthenia gravis patients.
Romi F; Skeie GO; Aarli JA; Gilhus NE
J Neurol; 2000 May; 247(5):369-75. PubMed ID: 10896269
[TBL] [Abstract][Full Text] [Related]
8. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens.
Zisimopoulou P; Brenner T; Trakas N; Tzartos SJ
Autoimmun Rev; 2013 Jul; 12(9):924-30. PubMed ID: 23537507
[TBL] [Abstract][Full Text] [Related]
9. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
[TBL] [Abstract][Full Text] [Related]
10. Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis.
Shelton GD; Skeie GO; Kass PH; Aarli JA
Vet Immunol Immunopathol; 2001 Jan; 78(1):97-105. PubMed ID: 11182151
[TBL] [Abstract][Full Text] [Related]
11. Multiple antibody detection in 'seronegative' myasthenia gravis patients.
Hong Y; Zisimopoulou P; Trakas N; Karagiorgou K; Stergiou C; Skeie GO; Hao HJ; Gao X; Owe JF; Zhang X; Yue YX; Romi F; Wang Q; Li HF; Gilhus NE; Tzartos SJ
Eur J Neurol; 2017 Jun; 24(6):844-850. PubMed ID: 28470860
[TBL] [Abstract][Full Text] [Related]
12. Antititin antibody in early- and late-onset myasthenia gravis.
Szczudlik P; Szyluk B; Lipowska M; Ryniewicz B; Kubiszewska J; Dutkiewicz M; Gilhus NE; Kostera-Pruszczyk A
Acta Neurol Scand; 2014 Oct; 130(4):229-33. PubMed ID: 24947881
[TBL] [Abstract][Full Text] [Related]
13. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis.
Romi F; Gilhus NE; Varhaug JE; Myking A; Skeie GO; Aarli JA
Eur J Neurol; 2002 Jan; 9(1):55-61. PubMed ID: 11784377
[TBL] [Abstract][Full Text] [Related]
14. MuSK-antibody-positive myasthenia gravis in a South Asian population.
Chang T; Gunaratne P; Gamage R; Riffsy MT; Vincent A
J Neurol Sci; 2009 Sep; 284(1-2):33-5. PubMed ID: 19394052
[TBL] [Abstract][Full Text] [Related]
15. Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome.
Yildiz Celik S; Durmus H; Yilmaz V; Saruhan Direskeneli G; Gulsen Parman Y; Serdaroglu Oflazer P; Deymeer F
Acta Neurol Belg; 2020 Feb; 120(1):133-140. PubMed ID: 31811563
[TBL] [Abstract][Full Text] [Related]
16. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
17. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L
Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.
Cortés-Vicente E; Gallardo E; Martínez MÁ; Díaz-Manera J; Querol L; Rojas-García R; Illa I
JAMA Neurol; 2016 Sep; 73(9):1099-104. PubMed ID: 27379450
[TBL] [Abstract][Full Text] [Related]
19. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
Lazaridis K; Tzartos SJ
Front Immunol; 2020; 11():212. PubMed ID: 32117321
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
Mygland A; Vincent A; Newsom-Davis J; Kaminski H; Zorzato F; Agius M; Gilhus NE; Aarli JA
Arch Neurol; 2000 Apr; 57(4):527-31. PubMed ID: 10768628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
